Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 4
Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Rapid Communication

The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Satoshi Itoa Department of Rheumatology, Niigata Rheumatic Center, Shibata, JapanCorrespondence[email protected]
,
Shunsuke Sakaia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
,
Yoichi Kurosawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
,
Daisuke Kobayashia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan;b Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
,
Ryo Okabayashia Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
,
Asami Abea Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
,
Hiroshi Otania Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
,
Kiyoshi Nakazonoa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
,
Akira Murasawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
,
Ichiei Naritab Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
&
Hajime Ishikawaa Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan
 show all
Pages 919-923 | Received 05 Jun 2020, Accepted 04 Sep 2020, Published online: 12 Oct 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Conflict of interest

S. Ito received a speaking fee (approximately US$ 5000) from Eisai Co., Ltd.; Mitsubishi Tanabe Pharma Co., Ltd., and Janssen pharmaceutical K.K. The other authors declare no conflicts of interest in association with this study.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
There are no offers available at the current time.

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.